Exclusive Summary

• Ketoprofen Patch is a fully off-patent generic product with no remaining IP barriers in major global markets, allowing Chinese suppliers to compete on price and compliance across Europe, Asia, and emerging markets.
• The addressable patient population is enormous—over 1.7 billion people suffer from chronic pain globally, with musculoskeletal disorders being the leading cause of disability, providing a stable and growing demand base for topical NSAID patches.
• The topical route of administration offers a clinically meaningful advantage over oral NSAIDs by minimizing systemic GI and cardiovascular risks, making it a guideline-preferred option for elderly and comorbid patients in aging markets such as Japan, Germany, and South Korea.
• Offering both 20mg and 40mg strengths enables flexible matching to different market dosing conventions and prescription patterns, broadening the range of potential distribution partners.
• Chinese manufacturers can offer Ketoprofen Patch at 30–60% lower cost than European-origin generics, giving distribution partners a compelling margin advantage or a stronger competitive price position at the end market.